Medical Advisory Board

Dr. Suresh Chari

Cleveland Mayo Clinic

William K. Oh

Special Advisor

Giuseppe Del Priore, MD, MPH

Chief Medical Officer

DR. SURESH CHARI

Cleveland Mayo Clinic

Suresh Chari, M.D. is a Professor of Medicine at the Mayo Clinic College of Medicine. He is also a consultant in the Division of Gastroenterology. He is Head of the Pancreas Interest Group in the Division of Gastroenterology and Hepatology. Dr. Chari has a broad interest in diseases of the pancreas and his NIH-funded research focuses on the role of diabetes and hyperglycemia as a marker of undiagnosed pancreatic cancer. Additional areas of clinical research involve understanding the clinical spectrum of autoimmune pancreatitis and he is also interested in cystic tumors of the pancreas including their classification, prevalence, and natural history.

William K. Oh

Special Advisor

William K. Oh, M.D. is the Chief of the Division of Hematology and Medical Oncology; Professor of Medicine and Urology; and Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine and Associate Director for Clinical Research, The Tisch Cancer Institute.

Clinical Interests: Management of genitourinary malignancies, including prostate, renal, bladder, adrenocortical and testicular cancers.

Research Interests: Dr. Oh’s research interests include exploring the role of chemotherapy in both castration-resistant prostate cancer (CRPC) and localized high-risk prostate cancer. In collaboration with laboratory-based colleagues, we are assessing changes in the expression of tissue and serum biomarkers due to chemotherapy. Another area of interest relates to the role of secondary hormone therapies in the treatment of advanced prostate cancer.

Another major research area has been the development and management of a prospective clinical database linked to blood and tissue banks for prostate cancer patients. Dr. Oh’s recent research efforts exploring this database have included characterization of the efficacy of various therapies in advanced prostate cancer (e.g., nilutamide, ketoconazole, vinorelbine, docetaxel, mitoxantrone), assessment of PSA doubling time as a prognostic and predictive factor, efficacy of hormonal therapy, assessment of testosterone as a marker for cancer outcome, prediction of relapse based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score.

DR. GIUSEPPE DEL PRIORE

Chief Medical Officer

Dr. Del Priore joined Tyme Inc. after serving as the National Director of Gynecologic Oncology for Cancer Treatment Centers of America (CTCA). He also serves as the Southeastern Regional Director. Prior to CTCA, Dr. Del Priore was Professor and Director of Gynecologic Oncology at the Indiana University School of Medicine in Indianapolis, where he directed its gynecologic oncology fellowship program and continues to teach. He previously also served as Director of Gynecologic Oncology at New York Downtown Hospital, Montefiore Medical Center, and Bellevue Hospital in New York City, as well as Assistant Director of Gynecologic Oncology at New York University School of Medicine. Giuseppe Del Priore, MD, MPH has been involved with drug, device and procedure development his entire career. He has participated and been on the advisory boards of studies for most major pharmaceutical companies. An industry KOL, his opinions have earned him invitations to present at the FDA and other regulatory agencies. His work has been reported on the front pages of the NY Times, WSJ and nearly every media outlet. He has been the principle investigator on several world firsts including breakthroughs in oncology, fertility and other areas of science. Dr. Del Priore remains a sought after clinician bringing relevant insights from actual patient challenges directly to the board room. Dr. Del Priore earned his Doctor of Medicine with Distinction in Research from State University of New York Downstate Medical Center in Brooklyn. He studied at The City University of New York’s Brooklyn College in a combined Bachelor of Arts/Doctor of Medicine Program, earning both degrees in seven years. Dr. Del Priore graduated magna cum laude with a Bachelor of Arts in Philosophy and was valedictorian of his medical school class. He received his Master of Public Health in Biostatistics and Epidemiology from the University of Illinois at Chicago and completed other training at Northwestern University and the University of Rochester. 

U.S. News and World Report named Dr. Del Priore one of its “Best Doctors” in 2011 and 2012.

He is an active researcher and prolific writer. He has authored and published more than 170 papers, book chapters, and abstracts and written three books. Dr. Del Priore has received two patents and has others pending. He has served on several committees and organizations, including current appointments at the Society of Gynecologic Oncologists; and previously the Gynecologic Oncology Group, a National Cancer Institute Cooperative Group. He is also an examiner for the American Osteopathic Association Board of Obstetrics and Gynecology, Gyn Oncology subspecialty section. In his free time, Dr. Del Priore has given back to his community by serving as a volunteer physicians part of the National Association of Free and Charitable Clinics; a volunteer firefighter in Westchester County, New York; an auxiliary police officer with the New York Police Department; and a volunteer ambulance driver with the Bay Ridge Ambulance Volunteer Organization.